Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment

Michel Krempf, Philippe Costet, Sanae Kourimate, Thierry Pineau, Abstract 1023: Proprotein Convertase Subtilisin Kexin type 9 is repressed by the Peroxisome Proliferator Activated Receptor alpha ligand fenofibric acid. Circulation. ,vol. 114, ,(2006)

Thomas Lagace, Yetsa Tuakli-Wosornu, Jay Horton, Helen H Hobbs, Zhenze Zhao, Jonathan C Cohen, Abstract 1022: Genetic Deficiency of Proprotein Convertase Subtilisin/Kexin 9: Identification of a Compound Heterozygote with no PCSK9 Circulation. ,vol. 114, ,(2006)

Glen Spraggon, Eric N. Hampton, Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof ,(2008)

Gary Swergold, Scott Mellis, William J. Sasiela, Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations ,(2014)

M Kenneth Jr, Scott M LeGrand, None, The Protein Folding Problem and Tertiary Structure Prediction ,(2012)

Marie-Paule Lefranc, Gérard Lefranc, The Immunoglobulin FactsBook ,(2001)

Craig Rosen, Steven Ruben, 621 human secreted proteins ,(2003)

Lillian Wei-Ming Chiang, Andrew Wood, Lorayne P. Jenkins, Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor ,(2011)

Glenn A Friedrich, Nicholas England, E-Chiang Lee, Mark Strivens, Allan Bradley, Antibodies, variable domains&chains tailored for human use ,(2012)

Craig Rosen, Steven Ruben, 251 human secreted proteins ,(2003)